Onderzoeker
Siel Olbrecht
- Disciplines:Gynaecologie en verloskunde, Verpleegkunde, Endocrinologie en metabole ziekten
Affiliaties
- Gynaecologische Oncologie (Afdeling)
Lid
Vanaf16 mrt 2017 → 9 aug 2021
Projecten
1 - 1 of 1
- De analyse van het hooggradig sereus adenocarcinoma van tubo-ovariële origine door middel van single-cell RNA-sequencingVanaf1 mrt 2017 → 5 jul 2021Financiering: Eigen Middelen zoals patrimonium, inschrijvingsgelden, giften, ....
Publicaties
1 - 10 van 13
- Systematic study of tissue factor expression in solid tumors(2023)
Auteurs: Siel Olbrecht, Ignace Vergote
- Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer(2022)
Auteurs: Pieter Busschaert, Siel Olbrecht, An Coosemans, Wouter Froyman, Liselore Loverix, Els Van Nieuwenhuysen, Sileny Han, Toon Van Gorp, Tom Venken, Ruben Heremans, et al.
- Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer(2022)
Auteurs: Liselore Loverix, Pieter Busschaert, Els Van Nieuwenhuysen, Sileny Han, Siel Olbrecht, Patrick Neven, Diether Lambrechts, Toon Van Gorp, Ignace Vergote
Pagina's: 14 - 22 - MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma(2022)
Auteurs: Diether Lambrechts, Liselore Loverix, Siel Olbrecht, Ignace Vergote
Pagina's: 855 - 871 - Polygenic risk modeling for prediction of epithelial ovarian cancer risk(2022)
Auteurs: Diether Lambrechts, Siel Olbrecht
Pagina's: 349 - 362 - High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification(2021)
Auteurs: Siel Olbrecht, Pieter Busschaert, Jun Qian, Liselore Loverix, Toon Van Gorp, Els Van Nieuwenhuysen, Sileny Han, An Coosemans, Anne-Sophie Van Rompuy, Diether Lambrechts, et al.
- Comprehensive transcriptomic analysis of high-grade serous tubo-ovarian carcinoma using single-cell RNA-sequencing.(2021)
Auteurs: Siel Olbrecht, Ignace Vergote, Diether Lambrechts
- Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: Results from the randomized phase II CLIO trial(2020)
Auteurs: A Vanderstichele, L Loverix, C De Vogelaere, L Heyrman, T Van Gorp, E Van Nieuwenhuysen, S Han, Siel Olbrecht, P Berteloot, P Neven, et al.
Pagina's: S617 - S618 - A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling(2020)
Auteurs: Siel Olbrecht, Bram Boeckx, Hanne Vos, H. Emre Etlioglu, Els Wauters, Sara Verbandt, Pieter Busschaert, Ayse Bassez, Jieyi Xiong, Birgit Weynand, et al.
Pagina's: 745 - 762 - ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease(2019)
Auteurs: Ignace Vergote, Thaïs Baert, Siel Olbrecht
Pagina's: 728 - 760